Leuven, 14 June 2024 - Frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) are two devastating neurodegenerative diseases. Scientists have long suspected a protein called FUS might ...
An experimental drug could help young people with a rare form of ALS, researchers at New York’s Columbia University Irving Medical Center announced on Thursday. Known as “ulefnersen,” the therapy ...
As neurologists and neurobiologists gathered for the Third International Research Workshop on Frontotemporal Dementia in ALS, 21-25 June in London, Ontario, Canada, the big buzz was all about Fused in ...
The remaining 10% of ALS cases are hereditary and linked to mutations in one of more than 30 distinct genes involved in different cellular processes. There are severe early onset and juvenile cases, ...
A new study from scientists at VIB-KU Leuven Center for Brain & Disease and elsewhere reveals the role of an RNA binding protein called Fused in Sarcoma (FUS) in the development of frontotemporal ...
When Columbia neurologist and scientist Neil Shneider speaks to his ALS patients who volunteer for experimental therapies, he's unwaveringly honest. "Patients always ask me, 'What can I hope to get ...
Typically, the goal of ALS treatments is to slow the disease or halt progression. But new data from the antisense oligonucleotide (ASO) jacifusen for FUS-ALS show that two patients went beyond the ...
Scientists have found that the protein histone H1.2 and the enzyme PARP1 could be potential therapeutic targets to decrease neurodegeneration in amyotrophic lateral sclerosis (ALS). Amyotrophic ...
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease which remains incurable. The disease is characterized by the selective degeneration of upper motor neurons in the motor cortex as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results